Late Tuesday, Vivakor, Inc. announced that they expanded the market for VivaSight Technologies to adult vision care. In addition, the Company further increased their revenue outlook for their VivaSight division.

Mr. Matt Nicosia, Vivakor Inc.’s Chairman, said, “Adult vision care is a growing market with an aging population. Existing vision screening devices do not properly detect adult issues and our technology has the capability of addressing this need. VivaSight technology is useful mainly for children’s screening but has the potential to be a very valuable asset in adult vision care. Our devices use cutting edge technology developed by our multidisciplinary research model to save time and money while enhancing exactness in all our detection efforts.”

The new market primarily includes adult vision care that Ophthalmologists and Optometrists will use. In addition, Vivakor will market VivaSight technologies as the best and most versatile vision screening devices on the market.

Mr. Nicosia stated, “The market for vision screening is not just limited to United States vision care. We have received significant attention through our commercialization partners for international use of the VivaSight technology for both private practice and government mandated vision care.”

This announcement will expand upon Vivakor Inc.’s recently released revenue projections for their VivaSight division and increase the estimated market to $50 million each year.

Vivakor, Inc. is a biomedical/biotechnology company. They have transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. They also provide contract research services for third parties.

Vivakor’s business model is to be a research center focused on areas that have both an identified scientific need and a significant market opportunity. Their corporate mission is to advance new ideas to improve the quality of life for individual patients, researchers, clinician, or consumer.

For more information visit: